Back to search
FDAFDA · Food and drugs·Recall number D-0568-2022

Pyrazinamide Tablets, USP 500 mg, 100-count bottles, Rx only, Manufactured by: ULTRAtab Laboratories, Inc. Highland, NY 12528, Distributed by Par Pharmaceuticals, Chestnut Ridge, NY 10977, NDC 67253-660-10.

Published February 23, 2022 · Recall initiated: February 15, 2022

Summary

FDA records drug Class II recall D-0568-2022, published February 23, 2022 and initiated February 15, 2022. Recalling firm: ANI Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 5,477 bottles; Lot: Lot #: 19B064A, Exp. Date 03/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
ANI Pharmaceuticals, Inc.
Distributor
Nationwide within the United States
Lot
Lot #: 19B064A, Exp. Date 03/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Pyrazinamide Tablets, USP 500 mg, 100-count bottles, Rx only, Manufactured by: ULTRAtab Laboratories, Inc. Highland, NY 12528, Distributed by Par Pharmaceuticals, Chestnut Ridge, NY 10977, NDC 67253-660-10. recalled?

Yes. FDA published recall D-0568-2022 on February 23, 2022. Reported hazard: cGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter